Breast Cancer
Neoadjuvant docetaxel combined with adjuvant doxorubicin and cyclophosphamide
Published in Women's Health Weekly, October 13th, 2005
Researchers in the United States conducted a study "to evaluate clinical and pathologic response to neoadjuvant docetaxel therapy in patients with stage III breast cancer. Forty-five patients were planned to receive four cycles of docetaxel 100 mg/m2 every 3 weeks, followed by surgery, four cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) every 3 weeks, radiation therapy (RT), and tamoxifen when indicated."
"After four cycles of neoadjuvant docetaxel, the clinical response rate within the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Back Pain
Teriparatide tested against alendronate for back pain in women with osteoporosis - Breast Cancer
Osteonectin expression inhibited MDA-MB-231 breast cancer cell metastasis - Cancer Risk Factors
EMSY gene evaluated for association in breast and ovarian cancer risk - Hormones
Role of circulating androgens in mid-life women examined - Medical Devices
Trocar-associated injuries and fatalities examined - Adverse Drug Reaction
Australian Agency urges caution over Paroxetine during pregnancy - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
